TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11763976

Group type: EXPERIMENTAL
Intervention: Oral administration of 400 microg misoprostol, 8 h before aspiration
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Vaginal self‐administration of 400 microg misoprostol, 4 h before aspiration
Number of subjects: 900
Study: 9409230

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (5 g eicosapentaenoic acid and docosahexaenoic acid per day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Antioxidants (75 mg vitamin E, 150 mg vitamin C, 15 mg beta-carotene, and 30 mg coenzyme Q10 per day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and antioxidants
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control oils
Number of subjects: 41
Study: 8513310

Group type: EXPERIMENTAL
Intervention: Amlodipine (A) 5,10mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitrendipine (N) 10,20mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 50
Study: 3321849

Group type: EXPERIMENTAL
Intervention: Cisapride (4 mg, i.v. injection)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 30378090

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27357095

Group type: EXPERIMENTAL
Intervention: Zinc carnosine (ZnC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Zinc carnosine (ZnC) plus bovine colostrum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: In vitro studies with ZnC or colostrum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination treatment (ZnC + colostrum)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 24778433

Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 0
Study: 23311173

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicines (Xiaozhi decoction), twice daily for 6 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Western medicine (0.5 g azithromycin for 3 days, 6 courses of treatment, each course lasting 4 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (32 infertile women with negative mycoplasma culture)
Number of subjects: 72
Study: 20624316

Group type: EXPERIMENTAL
Intervention: 30-minute daily physical education sessions based on early psychomotor education
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 30-minute daily physical education sessions
Number of subjects: 41
Study: 18179460

Group type: EXPERIMENTAL
Intervention: Flexible-dose sildenafil for ED treatment
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 16565867

Group type: EXPERIMENTAL
Intervention: Telemedicine support (Health Buddy computer providing daily Internet-based support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study: 12037369

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulation containing stannous fluoride (SnF(2))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulation containing sodium fluoride (NaF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SnF(2) positive control
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaF positive control
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-fluoride placebo negative control
Number of subjects: 0
Study: 10447990

Group type: EXPERIMENTAL
Intervention: Right mouth asymmetry (RMA) during speech production
Number of subjects: 20
Study: 8573730

Group type: EXPERIMENTAL
Intervention: Manidipine (20 mg/day)
Number of subjects: 7
Study: 2128700

Group type: EXPERIMENTAL
Intervention: Requirement-adapted peripheral-venous parenteral nutrition with maltose and fat emulsion (650 mosm/l; 2,000 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common requirement-adapted parenteral nutrition regimen via central-venous catheter (2,000 mosm/l; 2,000 kcal)
Number of subjects: 0
Study: 911576

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidocaine
Number of subjects: 0
Study: 31564377

Group type: EXPERIMENTAL
Intervention: Higher plasma α‐linolenic acid levels
Number of subjects: 426824

Group type: EXPERIMENTAL
Intervention: Higher plasma linoleic acid levels
Number of subjects: 426824

Group type: EXPERIMENTAL
Intervention: Higher plasma palmitoleic acid levels
Number of subjects: 426824

Group type: EXPERIMENTAL
Intervention: Higher plasma oleic acid levels
Number of subjects: 426824

Group type: EXPERIMENTAL
Intervention: Higher plasma arachidonic acid levels
Number of subjects: 426824

Group type: EXPERIMENTAL
Intervention: Higher plasma eicosapentaenoic acid levels
Number of subjects: 426824

Group type: EXPERIMENTAL
Intervention: Higher plasma docosapentanenoic acid levels
Number of subjects: 426824

Group type: EXPERIMENTAL
Intervention: Higher plasma stearic acid levels
Number of subjects: 426824
Study: 30234850

Group type: EXPERIMENTAL
Intervention: (-)-OSU6162
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 29173735

Group type: EXPERIMENTAL
Intervention: Lurasidone 20 to 80 mg/day
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 25500487

Group type: EXPERIMENTAL
Intervention: 50 mg canagliflozin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 300 mg canagliflozin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: canagliflozin (all doses)
Number of subjects: 27
Study: 23816023

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) bolus abciximab
Number of subjects: 452

Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 452

Group type: COMPARATOR
Intervention: No aspiration
Number of subjects: 452
Study: 21801326

Group type: EXPERIMENTAL
Intervention: Sitting posture
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standing posture
Number of subjects: 115
Study: 19454544

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (cLMA)
Number of subjects: 46
Study: 15193684

Group type: EXPERIMENTAL
Intervention: Chylomicron‐like emulsion labeled with radioactive triglyceride (3H‐TG) and cholesteryl esters (14C‐CE)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Delayed intravascular TG lipolysis
Number of subjects: 63
Study: 11239981

Group type: EXPERIMENTAL
Intervention: Selective attention procedure with odorants in mixtures of one to four components (Experiment 1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Profiling procedure with 146 descriptors for odor qualities (Experiment 2)
Number of subjects: 35
Study: 11185629

Group type: EXPERIMENTAL
Intervention: Oral administration of [14C]telmisartan 40 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [14C]telmisartan 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both oral and intravenous administration
Number of subjects: 10
Study: 8842072

Group type: EXPERIMENTAL
Intervention: Posturography and clinical assessment (physical examination, dizziness provocation, and psychological assessment)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Clinical diagnostic criteria based on accepted definitions
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Common diagnoses identified
Number of subjects: 149

Group type: COMPARATOR
Intervention: Blood profile, electrocardiography, electronystagmography, and magnetic resonance imaging
Number of subjects: 149
Study: 1537780

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (CMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6434117

Group type: EXPERIMENTAL
Intervention: Low dose antacid (10 ml as required)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Low dose placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High dose antacid (30 ml seven times daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: High dose placebo
Number of subjects: 69
Study: 29420230

Group type: EXPERIMENTAL
Intervention: Various recruitment strategies including providing trial information in the prehospital setting, technology for covering multiple sites, screening logs, and verbal consent.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nested RCT evaluating a recruitment intervention.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Reports of recruitment experiences from real RCTs and hypothetical RCTs.
Number of subjects: 39
Study: 27085660

Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA) plus Best Medical Treatment (BMT)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting (CAS) plus Best Medical Treatment (BMT)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Best Medical Treatment (BMT) alone
Number of subjects: 513
Study: 24581465

Group type: EXPERIMENTAL
Intervention: Port infection group (33 patients with infection)
Number of subjects: 4404

Group type: COMPARATOR
Intervention: Control group (66 patients with no infection)
Number of subjects: 4404

Group type: EXPERIMENTAL
Intervention: Port infection group
Number of subjects: 4404
Study: 22672186

Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 0
Study: 19889649

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES) with biodegradable polymer
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) with durable polymer
Number of subjects: 56
Study: 17966008

Group type: EXPERIMENTAL
Intervention: Dalteparin (n = 136)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo (n = 136)
Number of subjects: 272
Study: 16340371

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleting filter at 35 degrees C
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleting filter at 28 degrees C
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-leukocyte-depleting filter (Control) at 35 degrees C
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-leukocyte-depleting filter (Control) at 28 degrees C
Number of subjects: 80
Study: 12410513

Group type: COMPARATOR
Intervention: iodixanol 320 (Visipaque)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 618
Study: 9883284

Group type: EXPERIMENTAL
Intervention: 10-hour small-group informational and skill-building intervention
Number of subjects: 472

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 472
Study: 7612715

Group type: EXPERIMENTAL
Intervention: Nocturnal nasogastric tube feeding (30% additional caloric charge)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral feeding ad libitum (control group)
Number of subjects: 16
Study: 2773895

Group type: EXPERIMENTAL
Intervention: 180 mmol acetate plus 60 mmol propionate (180 mM; hypertonic)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 90 mmol sodium acetate plus 30 mmol sodium propionate (90 mM; isotonic)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 6
Study: 30267607

Group type: EXPERIMENTAL
Intervention: Unstructured playtime in natural environments
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Barriers and facilitators to play
Number of subjects: 29
Study: 29741754

Group type: EXPERIMENTAL
Intervention: Probiotics (2 capsules of Lactobacillus rhamnosus GG daily for 6 months)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo (calcium carbonate)
Number of subjects: 209
Study: 26674898

Group type: EXPERIMENTAL
Intervention: 1 g (2 × 500 mg) tranexamic acid tablets before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25140000

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy combined with bevacizumab
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High EGFL7 VA
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: miR126 vessel area (VA)
Number of subjects: 158
Study: 22363673

Group type: EXPERIMENTAL
Intervention: AZT monotherapy
Number of subjects: 23
Study: 19148838

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids in patients with prior myocardial infarction (MI)
Number of subjects: 20997

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids in patients with angina
Number of subjects: 20997

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 20997
Study: 18626295

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) + imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) + placebo
Number of subjects: 0
Study: 16043433

Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acamprosate (ACP)
Number of subjects: 100
Study: 12442934

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10325832

Group type: EXPERIMENTAL
Intervention: Global haemodynamic variables
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure on admission
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure at 12 h
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mean pulmonary artery pressure on admission
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mean pulmonary artery pressure at 12 h
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Gastric pHi on admission
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Gastric pHi at 12 h
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: delta PCO2 on admission
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: delta PCO2 at 12 h
Number of subjects: 68
Study: 8965037

Group type: EXPERIMENTAL
Intervention: Topical steroid injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deltoid muscle injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1743321

Group type: EXPERIMENTAL
Intervention: 5 micrograms GnRH pulse dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 micrograms GnRH pulse dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 micrograms GnRH pulse dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Induction cycles
Number of subjects: 15

Group type: COMPARATOR
Intervention: Spontaneous menstrual cycles
Number of subjects: 15
Study: 7039017

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High oral doses of prednisone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (RATG and prednisone)
Number of subjects: 20
Study: 30586746

Group type: EXPERIMENTAL
Intervention: ALD-401 infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 100
Study: 29070115

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate combined with rituxan (targeted treatment group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-dose methotrexate combined with whole brain radiotherapy (traditional treatment group)
Number of subjects: 100
Study: 26091461

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) administered at a loading dose of 0.5 μg/kg for 10 minutes, followed by an infusion rate of 0.4 μg/kg/h from insufflation of the pneumoperitoneum to the end of surgery.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) administered as described above.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 92
Study: 23512419

Group type: EXPERIMENTAL
Intervention: Morphine 0.04 mg/kg iv followed by 0.01 mg/kg/h infusion for 24 h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 21235724

Group type: EXPERIMENTAL
Intervention: Vaginal prolapse surgery
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Abdominal prolapse surgery with incontinence surgery
Number of subjects: 65

Group type: COMPARATOR
Intervention: Abdominal prolapse surgery only
Number of subjects: 65
Study: 19893121

Group type: EXPERIMENTAL
Intervention: Filgrastim (Neupogen) administered systematically during antiviral therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Combination antiviral therapy (pegylated interferon alfa plus ribavirin) without Filgrastim
Number of subjects: 64
Study: 17536485

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 9.05 mmol (220 mg) magnesium/d for 72 d
Number of subjects: 11

Group type: COMPARATOR
Intervention: Basal diet with lactose placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Magnesium deprivation
Number of subjects: 11
Study: 15449150

Group type: EXPERIMENTAL
Intervention: UFT 600 mg/day preoperatively for 7 consecutive days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no chemotherapy or radiotherapy)
Number of subjects: 30
Study: 11374748

Group type: EXPERIMENTAL
Intervention: Self-construal activation (personal self-construals 'I')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-construal activation (social self-construals 'we')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-unrelated information processing styles (differentiation mind-set)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-unrelated information processing styles (integration mind-set)
Number of subjects: 0
Study: 9684137

Group type: EXPERIMENTAL
Intervention: Polyunsaturated phosphatidyl-choline (PPC)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Prolonged PPC therapy
Number of subjects: 176
Study: 8113778

Group type: EXPERIMENTAL
Intervention: Consumer case management team
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nonconsumer case management team
Number of subjects: 91
Study: 2541967

Group type: EXPERIMENTAL
Intervention: Treated capsules (Nonoxynol-9)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-treated capsules (Nonoxynol-9)
Number of subjects: 96
Study: 29607658

Group type: EXPERIMENTAL
Intervention: Presence of none of the conditions (mental illness, hazardous alcohol use, drug dependence)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Presence of all three conditions (mental illness, hazardous alcohol use, drug dependence)
Number of subjects: 106
Study: 27054712

Group type: EXPERIMENTAL
Intervention: Patient empowerment training
Number of subjects: 0
Study: 25654952

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) tonsillectomy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cold dissection (CD) tonsillectomy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both RF and CD techniques
Number of subjects: 114
Study: 23737387

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distraction intervention
Number of subjects: 0
Study: 20009954

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials in stroke research
Number of subjects: 0
Study: 18389499

Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LH)
Number of subjects: 41

Group type: COMPARATOR
Intervention: General anaesthesia (GH)
Number of subjects: 41
Study: 16231766

Group type: EXPERIMENTAL
Intervention: 25 microg x h(‐1) fentanyl and 4 mg x h(‐1) ketamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 25 microg x h(‐1) fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: 35 microg x h(‐1) subcutaneous fentanyl infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: 50 microg x h(‐1) subcutaneous fentanyl infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: 25 microg x h(‐1) fentanyl and 2 mg x h(‐1) ketamine
Number of subjects: 50
Study: 12220322

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: COMPARATOR
Intervention: Carbamazepine (placebo add-on treatment)
Number of subjects: 29
Study: 10197944

Group type: EXPERIMENTAL
Intervention: Numeric rating scale accompanied by an educational programme for nurses
Number of subjects: 0
Study: 7551775

Group type: EXPERIMENTAL
Intervention: Upright faces
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Upright and inverted faces
Number of subjects: 126
Study: 1969567

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (diuretics or beta-blockers)
Number of subjects: 37000
Study: 7026258

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31493956

Group type: EXPERIMENTAL
Intervention: Oxytocin-Augmented HIFU
Number of subjects: 60

Group type: COMPARATOR
Intervention: HIFU (Control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: UAE (Control)
Number of subjects: 60
Study: 28578427

Group type: EXPERIMENTAL
Intervention: 2.0 g glutamine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25811813

Group type: EXPERIMENTAL
Intervention: Sodium ingestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 23648352

Group type: EXPERIMENTAL
Intervention: Treatment for elevated serum muscle enzymes in HP patients
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Elevated serum muscle enzymes in HP patients
Number of subjects: 41
Study: 21849260

Group type: EXPERIMENTAL
Intervention: Carisbamate 1000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carisbamate 1500 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carisbamate (higher dosages)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carisbamate (<1000 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19956159

Group type: EXPERIMENTAL
Intervention: Cancer awareness measure (CAM)
Number of subjects: 1500
Study: 17245623

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate plus hydroxyurea (500 mg twice a day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate plus hydroxyurea
Number of subjects: 39
Study: 15491247

Group type: EXPERIMENTAL
Intervention: 75 microg of clonidine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 150 microg of clonidine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14